Scholarlink

<p>This study investigated the antiparkinsonian effect of combinations of ladasten (50 and 100 mg/kg) and fabomotizole (10 mg/kg) in a mouse parkinsonism model induced by a single administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 30 mg/kg). The combinations were shown to reduce the severity of various parkinsonian syndrome symptoms, including tremor, motor deficits, impaired motor coordination in the rotarod test, bradykinesia in the vertical rod test, and extrapyramidal rigidity in the footprint test, as compared to the active control. The combination of ladasten at a dose of 50 mg/kg and fabomotizole at a dose of 10 mg/kg demonstrated the greatest effect. The efficacy of the ladasten/fabomotizole combination was comparable to that of levodopa in the used behavioral testing battery.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Antiparkinsonian Effect of a Combination of Ladasten and Fabomotizole in an MPTP-Induced Parkinsonian Syndrome Model

  • 期刊论文

  • 发表日期：

    2026年1月1日

查看全文
  • V. E. Marievskii,
  • I. A. Lubanskii,
  • L. F. Zainullina

摘要

This study investigated the antiparkinsonian effect of combinations of ladasten (50 and 100 mg/kg) and fabomotizole (10 mg/kg) in a mouse parkinsonism model induced by a single administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 30 mg/kg). The combinations were shown to reduce the severity of various parkinsonian syndrome symptoms, including tremor, motor deficits, impaired motor coordination in the rotarod test, bradykinesia in the vertical rod test, and extrapyramidal rigidity in the footprint test, as compared to the active control. The combination of ladasten at a dose of 50 mg/kg and fabomotizole at a dose of 10 mg/kg demonstrated the greatest effect. The efficacy of the ladasten/fabomotizole combination was comparable to that of levodopa in the used behavioral testing battery.